Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis

Endocrine Practice

Volumn 15, Issue 6, 2009, Pages 573-579

  Lewiecki, E Michael ^a   Binkley, Neil ^b  

^a Osteoporosis Center   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; TESTOSTERONE; ZOLEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CIGARETTE SMOKING; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FALLING; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LIFESTYLE; MORPHOMETRICS; OSTEOLYSIS; OSTEOPOROSIS; PATIENT ASSESSMENT; PATIENT CARE; POSTMENOPAUSE OSTEOPOROSIS; POSTTRAUMATIC OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; THORAX RADIOGRAPHY; VERTEBRA FRACTURE; WRIST FRACTURE; EVIDENCE BASED MEDICINE; FEMALE; MALE; META ANALYSIS; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL;

EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 70349943665     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09107.RA     Document Type: Review

References (61)

1. Osler WO. William Osler Quotes. http://www.brainyquote.com/quotes/ quotes/w/williamosl386616.html. Accessed for verification April 26, 2009.
2. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
3. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666-673.
4. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int. 2000;11:533-536.
5. Field MJ, Lohr KN, eds (Institute of Medicine, Committee on Clinical Practice Guidelines). Guidelines for Clinical Practice: From Development to Use. Washington, DC: The National Academies Press, 1992.
6. Guyatt GH, Sackett DL, Cook DJ (Evidence-Based Medicine Working Group). Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? JAMA. 1993;270:2598-2601.
7. Oxman AD, Sackett DL, Guyatt GH (Evidence-Based Medicine Working Group). Users' guides to the medical literature. I. How to get started. JAMA. 1993;270:2093-2095.
8. Claridge JA, Fabian TC. History and development of evidence-based medicine. World J Surg. 2005;29:547-553.
9. Doherty S. History of evidence-based medicine: oranges, chloride of lime and leeches; barriers to teaching old dogs new tricks. Emerg Med Australas. 2005;17:314-321.
10. Doherty S. Evidence-based medicine: arguments for and against. Emerg Med Australas. 2005;17:307-313.
11. Wynder EL. A corner of history: James Lind's discovery of the causes of scurvy. Prev Med. 1974;3:300-305.
12. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. Br Med J. 1948;2: 769-782.
13. Parapia LA. History of bloodletting by phlebotomy. Br J Haematol. 2008;143:490-495.
14. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290:495-501.
15. Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003;290:516-523.
16. Olson CM, Rennie D, Cook D, et al. Publication bias in editorial decision making. JAMA. 2002;287:2825-2828.
17. Del Mar CB, Anderson JN. Epitaph for the EBM in action series. Med J Aust. 2003;178:535-536.
18. Haynes RB. What kind of evidence is it that evidence-based medicine advocates want health care providers and consumers to pay attention to? BMC Health Serv Res. 2002; 2:3.
19. Sehon SR, Stanley DE. A philosophical analysis of the evidence-based medicine debate. BMC Health Serv Res. 2003;3:14.
20. Straus SE. What's the E for EBM? BMJ. 2004;328: 535-536.
21. Grahame-Smith D. Evidence based medicine: socratic dissent. BMJ. 1995; 310:1126-1127.
22. Fisher ES, Goodman DC, Chandra A. Disparities in health and health care among Medicare beneficiaries. June 5, 2008. http://www.rwjf.org/pr/ product.jsp?id=31251. Accessed for verification April 26, 2009.
23. Bassler D, Busse JW, Karanicolas PJ, Guyatt GH. Evidence-based medicine targets the individual patient, part 2: guides and tools for individual decision-making. Evid Based Med. 2008;13: 130-131.
24. Bassler D, Busse JW, Karanicolas PJ, Guyatt GH. Evidence-based medicine targets the individual patient, part 1: how clinicians can use study results to determine optimal individual care. Evid Based Med. 2008;13:101-102.
25. Butcher G. Daniel and the Kings of Babylon. Vero Beach, FL: Rourke Publishing Group, 1984.
26. Shang Z, ed. Ben Cao Tu Jing (Atlas of Materia Medica) [in Chinese]. Anhui: Anhui Science and Technology Press, 1994.
27. van Helmont JB. Oriatrike, or physick refined: the common errors therein refuted and the whole are reformed and rectified. London: Lodowick Loyd, 1662.
28. Louis P. Researches on the effects of blood-letting in some inflammatory diseases, and on the influence of tartarised antimony and vesication in pneumonitis. Am J Med Sci. 1836;18:102-111.
29. Amberson JB, McMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuberc. 1931;24:401-435.
30. Field MJ, Lohr KN, eds (Institute of Medicine, Committee to Advise the Public Health Service on Clinical Practice Guidelines). Clinical Practice Guidelines: Directions for a New Program. Washington, DC: The National Academies Press, 1990.
31. Hayward RS, Wilson MC, Tunis SR, Bass EB, Guyatt G (Evidence-Based Medicine Working Group). Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? JAMA. 1995;274:570-574.
32. National Guideline Clearinghouse. NGC search results [for osteoporosis]. http://www.guideline.gov/search/searchresults.aspx?Type= 3&txtSearch=OSTEOPOROSIS&num=20. Accessed for verification April 26, 2009.
33. Lewiecki EM. Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep. 2005;3:75-83.
34. Kanis JA (World Health Organization Scientific Group). Assessment of Osteoporosis at the Primary Health Care Level [technical report]. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, 2008.
35. World Health Organization. FRAX-WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/. Accessed for verification April 26, 2009.
36. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;11:473-477.
37. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008. http://www.nof.org/professionals/clinicians-guide.htm. Accessed for verification April 26, 2009.
38. Tosteson AN, Melton LJ III, Dawson-Hughes B, et al (National Osteoporosis Foundation Guide Committee). Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437-447.
39. Zethraeus N, Borgström F, Ström O, Kanis JA, Jönsson B. Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int. 2007;18:9-23.
40. Gregoric P. Aristotle on the Common Sense. Oxford, UK: Oxford University Press, 2007.
41. Random House Webster's College Dictionary. New York, NY: Random House, 1999.
42. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327:1459-1461.
43. Sherman M. Evidence-based common sense [in English, French]? Can Fam Physician. 2008;54:166-171.
44. Dyck GH. Ginkgo or gunk? Can Fam Physician. 2008;54:681.
45. Dickson RC. Common sense is not that common. Can Fam Physician. 2008;54:681.
46. Cooper RF. Scepticism regarding common sense. Can Fam Physician. 2008;54:681-683.
47. Nannenga MR, Montori VM, Weymiller AJ, et al. A treatment decision aid may increase patient trust in the diabetes specialist: the Statin Choice randomized trial. Health Expect. 2009;12:38-44.
48. Olofsson H, Byberg L, Mohsen R, Melhus H, Lithell H, Michaëlsson K. Smoking and the risk of fracture in older men. J Bone Miner Res. 2005;20:1208-1215.
49. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323.
50. Johnell O, Kanis JA, Odén A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15: 175-179.
51. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (Osteoporotic Fractures Research Group). Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res. 1999;14:821-828.
52. Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11:75-91.
53. Actonel [package insert]. Mason, OH: Procter & Gamble Pharmaceuticals, Inc., 2008.
54. Reclast [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2008.
55. Fosamax [package insert]. West Point, PA: Merck & Co. Inc., 2005.
56. Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company, 2007.
57. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343: 604-610.
58. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int. 2006;26:427-431.
59. Black DM, Cummings SR, Karpf DB, et al (Fracture Intervention Trial Research Group). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
60. McClung MR, Geusens P, Miller PD, et al (HIP Intervention Program Study Group). Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-340.
61. Black DM, Delmas PD, Eastell R, et al (HORIZON Pivotal Fracture Trial). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.